J Hu,
A Yu, B Othmane, D Qiu, H Li, C Li, P Liu… - Theranostics, 2021 - ncbi.nlm.nih.gov
Rationale: Siglec15 is an emerging target for normalization cancer immunotherapy.
However, pan-cancer anti-Siglec15 treatment is not yet validated and the potential role of …